Who We Are and What We Do
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments.
GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases particularly where there is high unmet need. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline.
We are pleased now to be a public company traded on the NASDAQ under the symbol GLYC.